Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Chavicol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chavicol SCHEMBL3119862 | 0.92 | CA2 (0.50) | CYP1A2CYP2D6MAPK1HSD17B10ALDH1A1 | |
| Chavicol SCHEMBL10525947 | 0.88 | XDH (0.47) | CYP1A2CYP2D6MAPK1HSD17B10ALDH1A1 | |
| Chavicol SCHEMBL9745352 | 0.87 | ALDH1A1 (0.54) | CYP1A2CYP2D6MAPK1HSD17B10ALDH1A1 | |
| Chavicol SCHEMBL3871465 | 0.87 | XDH (0.54) | CYP1A2CYP2D6MAPK1HSD17B10ALDH1A1 | |
| Chavicol SCHEMBL30870 | 0.87 | XDH (0.58) | CYP1A2CYP2D6MAPK1HSD17B10ALDH1A1 | |
| Chavicol SCHEMBL11043594 | 0.85 | XDH (0.56) | CYP1A2CYP2D6MAPK1HSD17B10ALDH1A1 | |
| Chavicol SCHEMBL10565597 | 0.85 | XDH (0.56) | CYP1A2CYP2D6MAPK1HSD17B10ALDH1A1 | |
| Chavicol SCHEMBL7187339 | 0.85 | XDH (0.56) | CYP1A2CYP2D6MAPK1HSD17B10ALDH1A1 | |
| Chavicol SCHEMBL7924978 | 0.85 | XDH (0.56) | CYP1A2CYP2D6MAPK1HSD17B10ALDH1A1 | |
| Chavicol SCHEMBL10511637 | 0.85 | XDH (0.56) | CYP1A2CYP2D6MAPK1HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2952201-B1 | Compositions of Alpinia galanga or Alpinia conchigera with high content of 1'S-1'-acetoxychavicol acetate suitable for pharmaceutical use | NERTHUS APS (DK) | 2017-06-21 | — | — | EP | claimed |
| CN-101843591-A | 1'-acetoxyl chavicol acetate naonparticle | NANCHANG HELIOEAST SCIENCE AND TECHNOLOGY CO LTD | 2010-09-29 | — | — | CN | claimed |
| US-20260034186-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2026-02-05 | — | — | US | disclosed |
| US-12427176-B2 | Enriched mineral pitch resin products and methods of manufacturing enriched mineral pitch resin products | RIZUN NODARI (US) | 2025-09-30 | — | — | US | disclosed |
| WO-2024235510-A1 | ANTI-DANDRUFF COMPOSITIONS | ANALYTICON DISCOVERY GMBH (DE) | 2024-11-21 | — | — | WO | disclosed |
| EP-4464309-A1 | ANTIDANDRUFF COMPOSITION COMPRISING 1-ACETOXYCHAVICOL ACETATE | Analyticon Discovery GmbH (DE) | 2024-11-20 | — | — | EP | disclosed |
| US-20240216456-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240216457-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240207344-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240207342-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240207343-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2024-06-27 | — | — | US | disclosed |
| WO-1999053935-A1 | NOVEL SYNERGISTIC COMPOSITIONS CONTAINING AROMATIC COMPOUNDS AND TERPENOIDS PRESENT IN ALPINIA GALANGA | IDA DEVELOPMENT A/S (DK) | 1999-10-28 | — | — | WO | disclosed |
| EP-0882149-A1 | CARBOXYLIC ACID-CONTAINING POLYMER/RESOLE RESIN STAIN-RESISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-12-09 | — | — | EP | disclosed |
| US-5708087-A | Carboxylic acid-containing polymer/resole stain-resists | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-01-13 | — | — | US | disclosed |
| WO-1997031149-A1 | CARBOXYLIC ACID-CONTAINING POLYMER/RESOLE RESIN STAIN-RESISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-08-28 | — | — | WO | disclosed |
| WO-1996003442-A1 | FLUOROORGANIC SOIL-RESIST AGENTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-02-08 | — | — | WO | disclosed |
| US-5427859-A | Fluoroorganic soil-resist agents | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-06-27 | — | — | US | disclosed |
| US-5408010-A | Fluoroorganic soli-resist agents | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-04-18 | — | — | US | disclosed |
| US-5358769-A | Applying epoxy resin and hydrolyzed maleic anhydride copolymer | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-10-25 | — | — | US | disclosed |
| WO-1994018376-A1 | DURABLE HYDROLIZED MALEIC ANHYDRIDE POLYMER STAIN-RESISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034186-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | TRPV1, SOST, RUNX1 | ESR1 1617/4885ESR2 1839/4885CYP1A2 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.